Robert B. Raffa – författare

Developed decades ago to treat a legitimate medical need, benzodiazepines promisingly displaced less-effective and less-safe drugs, though prescribing has since exceeded their intended use and outpaced the available data. The current situation is characterized by excessive prescribing and extended utilization beyond good therapeutic practice. Evidence indicates that prolonged use of benzodiazepines causes a wide range of adverse reactions, and withdrawal can be particularly challenging. Misused, abused, diverted, and counterfeited, benzodiazepines have serious potential for substance use disorder, and are among the leading causes of drug-related overdose deaths. The Benzodiazepines Crisis sounds the alarm against the overuse of benzodiazepines, presenting an updated, evidence-based overview of this class of drugs and their negative consequences. Bringing together years of research, clinical expertise, and scientific evidence, this book aims to address a perceived lag between evidence and action in order to call for rational and dramatically reduced usage of benzodiazepines.

There have been tremendous recent advances in the pharmacotherapy, dose regimens, and combinations used to treat cancer and for the treatment or prevention of the spread of disease. As a direct result of these advances, there are an increasing number of cancer survivors, although research dealing with chemotherapy-induced pain is still in its early years. Written for pain management specialists, oncologists, pharmacologists, students, and primary care practitioners, Chemotherapy-Induced Neuropathic Pain provides insight into the important area of chemotherapy-induced neuropathic pain. It reviews the basic and clinical research into the normal physiology of pain transmission pathways, neuropathic pain pathology, the chemotherapeutic drug mechanisms of action and adverse effects, chemotherapy-induced neuropathy, and drug discovery efforts for treatment. The contributors comprise an impressive list of clinical and basic science experts in the fields of pain mechanisms and pain management. Included are clinical directors of pain clinics and clinical research facilities, directors of large academic pain research laboratories, analgesic drug developers, and presidents of the International Association for the Study of Pain (IASP), Association of Chronic Pain Patients (ACPP), and the British Pain Society (BPS). Through them, the book provides the reader with an exceptional opportunity to acquire a fundamental understanding of the basic concepts related to this topic.

Understanding and addressing the current opioid crisis requires knowledge of endogenous opioids (endorphins and enkephalins), but there is now evidence for a benzodiazepine crisis. Are there endogenous benzodiazepine-like substances—and what do they do? How do they affect antianxiety drugs and their adverse effects? Do they explain enigmatic prolonged benzodiazepine withdrawal syndrome? This book raises important questions about the clinical consequences of ignoring the existence of or understanding the potential influence of endogenous benzodiazepines on the therapeutic effect of benzodiazepines, their adverse effects, and the problems of withdrawal from them and other benzodiazepine receptor agonists.FEATURESDiscusses endogenous benzodiazepine-like substances—what do they do, and do they affect antianxiety drugs and their adverse effects?Presents information on enigmatic prolonged benzodiazepine withdrawal syndromeDescribes the compounds acting at the BDZ binding sites, both exogenous (classical BDZ drugs and BDZ from food and plants) and endogenous (endozepines)Assesses the putative interactions in physiology, pathology, and pharmacology of the compounds acting at the BDZ binding sitesDr. Raffa is Adjunct Professor at the University of Arizona College of Pharmacy and Professor Emeritus at Temple University School of Pharmacy. He has co-authored or edited several books on pharmacology and thermodynamics, is a co-editor of two journals, is a past president of the Mid-Atlantic Pharmacology Society, and is the recipient of research and teaching awards. Dr. Amantea is Associate Professor of Pharmacology at the Department of Pharmacy, Health and Nutritional Sciences of the University of Calabria (Italy), where she is the leader of the Stroke Research Unit at the Section of Preclinical and Translational Pharmacology operating in the frame of the Italian Stroke Organization (ISO) Basic Science. She is a member of the Editorial Board and the Guest Editor of the 2016 Neuroscience section of Current Opinion in Pharmacology (Elsevier), and the founder and the editor of the CRC Press Frontiers in Neurotherapeutics series.

The study of drug action has benefitted greatly from the development and use of in vivo model systems. In model systems, manipulations and observations can be more rigorously controlled and screens of novel therapeutic agents can be more safely conducted. No single model system provides all of the possible advantages. At one end, mammalian models allow the study of complex behavioral patterns and the most complex of cognitive functioning. At the other end, models using simple organisms such as C. elegans allow the application of the most sophisticated and recent molecular biology and other innovative techniques. The major purpose of the present book is to highlight another model-one that we believe occupies a uniquely important position.

Most adults take at least one prescription medication for example, for high blood pressure, high cholesterol levels, depression, asthma, diabetes, COPD, or a variety of other reasons, but most people (and many healthcare providers) are totally unaware that medications can have direct negative effects on sexual functioning and performance. This informative and timely book written by three well-known medications experts explores the chemistry behind sexual arousal in men and women and clearly and authoritatively explains how the common categories of prescription and over-the-counter medications and abused substances might be the reason for their declining sexual performance or even interest.

Most adults take at least one prescription medication for example, for high blood pressure, high cholesterol levels, depression, asthma, diabetes, COPD, or a variety of other reasons, but most people (and many healthcare providers) are totally unaware that medications can have direct negative effects on sexual functioning and performance. This informative and timely book written by three well-known medications experts explores the chemistry behind sexual arousal in men and women and clearly and authoritatively explains how the common categories of prescription and over-the-counter medications and abused substances might be the reason for their declining sexual performance or even interest.

Opioids such as morphine, codeine, and oxycodone are extracts or analogs isolated from a single source: the opium poppy. For a long time, it was believed to be nature’s only source of opioids. But it now appears that biological diversity has evolved an alternative source of opioid compounds—those derived from the plant Mitragyna speciosa. This plant, known as Kratom in Thailand or Biak-Biak in Malaysia, has long been used locally as treatment for pain, fever reduction, diarrhea, and even depression.Kratom and Other Mitragynines: The Chemistry and Pharmacology of Opioids from a Non-Opium Source presents an introduction to the chemical and biological properties of alkaloids isolated from M. speciosa as well as their synthetic analogs. The book covers various topics including phytochemistry, medicinal chemistry, and pharmacology. Current research, analgesic effects, and addiction potential are also discussed. As the first extensive text on the basic science and clinical use of Kratom, the book provides readers with a concise yet comprehensive introduction to nature’s "other opioid."

Kratom: History, Science and Therapeutic Potential is the first book to address the unregulated, widespread availability of kratom, with its weak opioid and stimulant effects, coupled with limited awareness of it by healthcare professionals. Kratom has great therapeutic utility and medicinal potential, but more study, caution, and possible regulation is needed. It discusses geographical sourcing, historical uses, current worldwide uses, and potential for treatment of other medical conditions. Most exciting for healthcare professionals will be the implications of this substance's potential for treatment of diseases like depression, ADHD, PTSD, and substance-use disorder, particularly opioid use disorder (OUD).Moreover, kratom and its active alkaloid mitragynine are getting remarkable attention at federal and local governments as more than eight million Americans consume this product annually. Yet, the paucity of information for researchers and clinicians is troublesome.Provides healthcare scientists and researchers with awareness on kratom and its emerging trend as a therapy for medical use for many medical applications Presents cutting-edge science for healthcare providers of a substance that will soon be as topical as medical marijuanaOffers scientists and others information to help those involved in emerging decisions regarding legal status and regulations

Drug-Receptor Thermodynamics is the first book to provide in depth coverage of principles and applications of thermodynamic drug-receptor interactions. The book starts from familiar points, making thermodynamics accessible to anyone interested in how drugs work. The ideas presented cover general principles as well as laying the groundwork for new ways of examining drug action.* covers an area of increasing interest and relevance in the field of drug design and discovery* excellent explanation of why thermodynamics is at the heart of drug action* contributions from many of the worlds leading experts in the fieldAnyone interested in drug receptor interaction will find something of use in this book. It will be of particular relevance for pharmacologists, health science researchers and medicinal chemists.

Understanding and addressing the current opioid crisis requires knowledge of endogenous opioids (endorphins and enkephalins), but there is now evidence for a benzodiazepine crisis. Are there endogenous benzodiazepine-like substances—and what do they do? How do they affect antianxiety drugs and their adverse effects? Do they explain enigmatic prolonged benzodiazepine withdrawal syndrome? This book raises important questions about the clinical consequences of ignoring the existence of or understanding the potential influence of endogenous benzodiazepines on the therapeutic effect of benzodiazepines, their adverse effects, and the problems of withdrawal from them and other benzodiazepine receptor agonists.FEATURESDiscusses endogenous benzodiazepine-like substances—what do they do, and do they affect antianxiety drugs and their adverse effects?Presents information on enigmatic prolonged benzodiazepine withdrawal syndromeDescribes the compounds acting at the BDZ binding sites, both exogenous (classical BDZ drugs and BDZ from food and plants) and endogenous (endozepines)Assesses the putative interactions in physiology, pathology, and pharmacology of the compounds acting at the BDZ binding sitesDr. Raffa is Adjunct Professor at the University of Arizona College of Pharmacy and Professor Emeritus at Temple University School of Pharmacy. He has co-authored or edited several books on pharmacology and thermodynamics, is a co-editor of two journals, is a past president of the Mid-Atlantic Pharmacology Society, and is the recipient of research and teaching awards. Dr. Amantea is Associate Professor of Pharmacology at the Department of Pharmacy, Health and Nutritional Sciences of the University of Calabria (Italy), where she is the leader of the Stroke Research Unit at the Section of Preclinical and Translational Pharmacology operating in the frame of the Italian Stroke Organization (ISO) Basic Science. She is a member of the Editorial Board and the Guest Editor of the 2016 Neuroscience section of Current Opinion in Pharmacology (Elsevier), and the founder and the editor of the CRC Press Frontiers in Neurotherapeutics series.

There have been tremendous recent advances in the pharmacotherapy, dose regimens, and combinations used to treat cancer and for the treatment or prevention of the spread of disease. As a direct result of these advances, there are an increasing number of cancer survivors, although research dealing with chemotherapy-induced pain is still in its early years. Written for pain management specialists, oncologists, pharmacologists, students, and primary care practitioners, Chemotherapy-Induced Neuropathic Pain provides insight into the important area of chemotherapy-induced neuropathic pain. It reviews the basic and clinical research into the normal physiology of pain transmission pathways, neuropathic pain pathology, the chemotherapeutic drug mechanisms of action and adverse effects, chemotherapy-induced neuropathy, and drug discovery efforts for treatment. The contributors comprise an impressive list of clinical and basic science experts in the fields of pain mechanisms and pain management. Included are clinical directors of pain clinics and clinical research facilities, directors of large academic pain research laboratories, analgesic drug developers, and presidents of the International Association for the Study of Pain (IASP), Association of Chronic Pain Patients (ACPP), and the British Pain Society (BPS). Through them, the book provides the reader with an exceptional opportunity to acquire a fundamental understanding of the basic concepts related to this topic.

Cancer patients have benefitted greatly from recent advances in the drugs, dose regimens, and combinations used to treat their primary tumor and for the treatment or prevention of spread of their disease. With the increase in survival rates, there has emerged a new awareness of these chronic adverse effects.

This book deals with principles in g

Opioids such as morphine, codeine, and oxycodone are extracts or analogs isolated from a single source: the opium poppy. For a long time, it was believed to be nature’s only source of opioids. But it now appears that biological diversity has evolved an alternative source of opioid compounds—those derived from the plant Mitragyna speciosa. This plant, known as Kratom in Thailand or Biak-Biak in Malaysia, has long been used locally as treatment for pain, fever reduction, diarrhea, and even depression.Kratom and Other Mitragynines: The Chemistry and Pharmacology of Opioids from a Non-Opium Source presents an introduction to the chemical and biological properties of alkaloids isolated from M. speciosa as well as their synthetic analogs. The book covers various topics including phytochemistry, medicinal chemistry, and pharmacology. Current research, analgesic effects, and addiction potential are also discussed. As the first extensive text on the basic science and clinical use of Kratom, the book provides readers with a concise yet comprehensive introduction to nature’s "other opioid."

Cancer patients have benefitted greatly from recent advances in the drugs, dose regimens, and combinations used to treat their primary tumor and for the treatment or prevention of spread of their disease. With the increase in survival rates, there has emerged a new awareness of these chronic adverse effects.